阿托伐他汀联合缬沙坦对慢性肾炎疗效及安全性评价.docVIP

阿托伐他汀联合缬沙坦对慢性肾炎疗效及安全性评价 　　[摘要] 目的 评估阿托伐他汀联合缬沙坦对慢性肾炎的疗效及安全性。 方法 选取2015年5月～2017年5月间在本院治疗的92例慢性肾炎患者作为研究对象，采用随机数字表法将患者分为研究组和对照组，各46例，两组患者均应用缬沙坦进行治疗，研究组患者在此基础上增用阿托伐他汀，观察两组患者治疗效果，包括治疗有效率、肾功能相关指标及不良反应发生率。 结果 治疗后，研究组患者Scr、BUN水平与对照组相近，差异无统计学意义（P0.05）；治疗后，研究组患者24 h pro、CRP水平均低于对照组，差异有统计学意义（P0.05）。 结论 阿托伐他汀联合缬沙坦对慢性肾炎患者疗效较好，安全性较高，值得广泛推荐。 　　[关键词] 阿托伐他汀；缬沙坦；慢性肾炎；肾功能 　　[中图分类号] R692 [文献标识码] B [文章编号] 1673-9701（2018）03-0041-03 　　Efficacy and safety evaluation of atorvastatin combined with valsartan on chronic nephritis 　　ZHANG Xuhong WANG Shaoxia 　　Department of Nephrology， Zhaoyuan City Peoples Hospital in Shandong Province， Zhaoyuan 265400， China 　　[Abstract] Objective To evaluate the efficacy and safety of atorvastatin combined with valsartan on chronic nephritis. Methods A total of 92 chronic nephritis patients treated in our hospital from May 2015 to May 2017 were selected in this study. The patients were divided into study group and control group by random number table method， with 46 cases in each group. Both groups of patients were treated with valsartan. And the study group was treated with atorvastatin on the above basis. The treatment effects of patients in two groups were observed. The observation indicators included treatment efficiency， renal function related indicators and the incidence of adverse reactions. Results After treatment， the levels of Scr and BUN in the study group were similar to those in the control group， and the difference was no statistically significant（P0.05）. After treatment， the levels of 24 h pro and CRP in the study group were significantly lower than those in the control group， and the difference was statistically significant（P0.05）. Conclusion Atorvastatin combined with valsartan is effective and safe for patients with chronic nephritis， which is worthy of wide recommendation. 　　[Key words] Atorvastatin； Valsartan； Chronic nephritis； Renal function 　　慢性?I炎是临床上常见的疾病，该病病程长，进展缓慢[1]。慢性肾炎患者主要表现为蛋白尿、水肿、高血压、血尿等症状，严重威胁患者健康和生命安全[2]。尿蛋白是慢性肾炎进展的